Cargando…

Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients

Despite excellent short-term graft survival after renal transplantation, the long-term graft outcome remains compromised. It has become evident that a combination of sustained alloreactivity and calcineurin-inhibitor- (CNI-) related nephrotoxicity results in fibrosis and consequently dysfunction of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bank, J. R., Rabelink, T. J., de Fijter, J. W., Reinders, M. E. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518147/ https://www.ncbi.nlm.nih.gov/pubmed/26258149 http://dx.doi.org/10.1155/2015/391797

Ejemplares similares

Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study
por: Reinders, Marlies E. J., et al.
Publicado: (2015)

Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients
por: Reinders, Marlies EJ, et al.
Publicado: (2014)

Cardiovascular Effects of Autologous Bone Marrow–Derived Mesenchymal Stromal Cell Therapy With Early Tacrolimus Withdrawal in Renal Transplant Recipients: An Analysis of the Randomized TRITON Study
por: Meucci, Maria Chiara, et al.
Publicado: (2021)

Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single‐center study
por: Dreyer, Geertje J., et al.
Publicado: (2020)

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics
por: Meziyerh, Soufian, et al.
Publicado: (2020)

Mesenchymal Stromal Cell-Based Therapy
por: Mönch, Dina, et al.
Publicado: (2023)

Autologous bone marrow‐derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single‐center, open‐label TRITON study
por: Reinders, Marlies E. J., et al.
Publicado: (2021)

Mesenchymal stromal cells in renal ischemia/reperfusion injury
por: de Vries, Dorottya K., et al.
Publicado: (2012)

Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC
por: Dreyer, Geertje J., et al.
Publicado: (2023)

Peripheral Blood Immune Cell Composition After Autologous MSC Infusion in Kidney Transplantation Recipients
por: Hendriks, Sanne H., et al.
Publicado: (2023)

The human kidney capsule contains a functionally distinct mesenchymal stromal cell population
por: Leuning, Daniëlle G., et al.
Publicado: (2017)

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients
por: Zwart, Tom C., et al.
Publicado: (2020)

Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive In vitro and in a Humanized Allograft Rejection Model
por: Roemeling-van Rhijn, Marieke, et al.
Publicado: (2013)

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
por: Bank, Jonna R., et al.
Publicado: (2016)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation
por: Naesens, Maarten, et al.
Publicado: (2022)

1592. Safety of Oral Trimethoprim/Sulfamethoxazole Prophylaxis in Renal Transplant Recipients
por: Horvat, Courtney, et al.
Publicado: (2018)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
por: Andrews, L. M., et al.
Publicado: (2019)

Mesenchymal Stromal Cell Therapy in Lung Transplantation
por: Nykänen, Antti I., et al.
Publicado: (2023)

Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation
por: Hilbrands, Luuk, et al.
Publicado: (2022)

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
por: Lacy, Steven, et al.
Publicado: (2018)

NK Cells and MSCs: Possible Implications for MSC Therapy in Renal Transplantation
por: Reinders, Marlies EJ, et al.
Publicado: (2014)

Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation
por: Podestà, Manuel Alfredo, et al.
Publicado: (2021)

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients
por: Brunkhorst, Lena Caroline, et al.
Publicado: (2015)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Fludrocortisone Therapy in Renal Transplant Recipients with Persistent Hyperkalemia
por: Marfo, K., et al.
Publicado: (2012)

A Novel Clinical Grade Isolation Method for Human Kidney Perivascular Stromal Cells
por: Leuning, Daniëlle G., et al.
Publicado: (2017)

Safety and Efficacy of the COVID-19 Vaccine in Kidney Transplant Recipients
por: Altheaby, Abdulrahman, et al.
Publicado: (2022)

Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn’s Disease
por: Busutti, Marco, et al.
Publicado: (2023)

Donor-Recipient Size Mismatch in Paediatric Renal Transplantation
por: Donati-Bourne, J., et al.
Publicado: (2014)

Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury
por: Bijkerk, Roel, et al.
Publicado: (2017)

Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients
por: Firth, Christine, et al.
Publicado: (2023)

Using Mesenchymal Stromal Cells in Islet Transplantation
por: Arzouni, Ahmed A., et al.
Publicado: (2018)

One-year Allograft and Patient Survival in Renal Transplant Recipients Receiving Antiplatelet Therapy at the Time of Transplantation
por: Benkö, T., et al.
Publicado: (2018)

Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant Recipients
por: Swarte, J. Casper, et al.
Publicado: (2020)

Use of pharmacogenomics in pediatric renal transplant recipients
por: Medeiros, Mara, et al.
Publicado: (2015)

Tuberculosis in renal transplant recipients
por: Sundaram, Madhivanan, et al.
Publicado: (2008)

Tuberculosis in renal transplant recipient
por: Kalita, P., et al.
Publicado: (2010)

Adipocytokines in renal transplant recipients
por: Nagy, Kristof, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mt6q0mhmafn2stit7bqugd8pmi